Advances in the treatment of chronic lymphocytic leukaemia - Speaker Series

In this review:

This publication is a summary of a recent presentation in New Zealand by Professor John Gribben, Chair of Medical Oncology at the Barts Cancer Institute, Queen Mary University of London, UK. The landscape for chronic lymphocytic leukaemia (CLL) treatment options in the USA and Europe has changed, with a number of novel agents for CLL recently receiving FDA and EMA approval. Professor Gribben discussed how these new agents are being applied and highlighted the ways in which these treatments will potentially enhance the management of patients with CLL.